论文部分内容阅读
Although the antiviral actions of interferons (IFNs) are first observed,up to date,Type Ⅰ IFNs (α/β) protein have been widely used as a clinical anticancer agent due to their antiproliferative effects via induction of apoptosis,activation of antitumor immunity and inhibition of angiogenesis etc.However,there are some limitations in antitumoral clinical trials of type Ⅰ IFNs such as short half-life and systemic toxicity at high doses.